Company: RVRC
Filing Date: 2025-10-03
Form Type: S-1/A
Source: 0001213900-25-096094
Chunk: 45

Company: Revium Rx.
Filing Date: 2025-10-03
Form: S-1/A
Chunk 45
---
<div align='center'>23</div>

Our future results may vary significantly, which may adversely affect the price of our Common Stock.

It is possible that our quarterly revenues and
operating results may vary significantly in the future and that period-to-period comparisons of our revenues and operating results are
not necessarily meaningful indicators of the future. You should not rely on the results of one quarter as an indication of our future
performance. It is also possible that in some future quarters, our revenues and operating results will fall below our expectations or
the expectations of market analysts and investors. If we do not meet these expectations, the price of our Common Stock may decline significantly.

The offer and sale of the Units by the Company in this Offering, the recent consummation of the Share Exchange with LipoVation, other acquisitions, and financing transactions could significantly dilute shareholder ownership and may cause it to become more susceptible to adverse economic events.

The offer and sale of Units, including the shares
of Common Stock, by the Company in the Primary Offering will result in the immediate dilution by the existing stockholders. In addition,
the existing stockholders may experience further dilution to the extent that our shares of Common Stock are issued upon the exercise of
any share options. See “Dilution” for a more complete description of how the value of your investment in our
Common Stock will be diluted upon completion of this offering. Furthermore, Company may use its Common Stock to acquire other companies
and may issue additional shares of Common Stock to pay for future acquisitions, which would dilute current investors’ ownership
interest in the Company. Future business acquisitions could be material to the Company, and the degree of success achieved in acquiring
and integrating these businesses into the Company could have a material effect on the value of the Company’s Common Stock. The closing
of the Share Exchange resulted in the issuance of 23,171,642 shares of our Common Stock, constituting 40% of the total issued and outstanding
shares of the Company’s Common Stock. As a result, the ownership of the Company’s Common Stock by existing stockholders would
be significantly diluted and might negatively affect the value of the Company’s Common Stock and the ability of the Company’s
stockholders to sell their shares of Common Stock on the market. Other potential acquisitions could require the Company to use other liquid
assets or to incur debt. In those events, the Company could become more susceptible to economic downturns and competitive pressures. In
addition, we may attempt to